Search

Trump EO Accelerates Psychedelic Drug Approvals for Mental Illness

President signs Executive Order 14401 directing federal agencies to accelerate research, approval, and access pathways for psychedelic drugs including ibogaine compounds for treatment-resistant serious mental illness. The FDA must prioritize National Priority Vouchers and Right to Try access, HHS must allocate at least $50 million through ARPA-H for state collaboration, and the Attorney General must initiate rescheduling review for Schedule I substances completing Phase 3 trials.